



For immediate release – July 26, 2007

## BUSINESS IS STRONG IN FIRST-HALF OF 2007: + 12.9%

Lure, France – July 26, 2007 – **For the six months ended 30 June 2007, Vétoquinol earned revenue of €111.1M, versus €98.4M over the same period one year earlier, an increase of 12.9%.**

On a constant exchange rate and scope of consolidation, the increase came to 10.1%.

All of the group's strategic regions made a contribution to this satisfactory revenue performance (Europe, North America and Asia). The biggest increase of the half-year came from Europe, and sales were up sharply in the United States thanks, in particular, to the successful integration of Vet Solutions in early 2007 and the synergies generated. In Asia, Vétoquinol benefited from the mounting strength of South Korea and the rollout of its product line throughout the region.

This growth also concerned all species, in particular companion animals or pets. Growth in this business primarily reflected the integration of Vet Solutions, which is exclusively focused on pets. As a result, the percentage of revenue from pet-related products rose in the first half of 2007, achieving a balance with sales of products for large farm animals.

*"Business should remain brisk in the second half of this year, with the introduction of new products planned for Europe in particular,"* noted Etienne Frechin, Chairman and CEO of Vétoquinol, *"although we expect growth to be less sustained than it was in the first half of 2007."*

Upcoming events: 2007 half-year earnings (Tuesday, 25 September 2007)  
Revenue through third quarter 2007 (Thursday, 25 October 2007)

### **About Vétoquinol**

*Vétoquinol, established in 1933, is an independent veterinary pharmaceutical laboratory for both food producing animals and pets. This family-owned Group, dedicated to animal health, is the world's 13<sup>th</sup> largest laboratory in its field. Nearly 80% of its revenue is now generated in export markets.*

*Its business includes research, production and marketing of drugs and health products. Vétoquinol, positioned in the treatment field, has extensive expertise in 3 major therapeutic fields: anti-infection agents, pain and anti-inflammatory, and cardiology-nephrology.*

*The Group now distributes its products in about one hundred countries (Europe, North America and Asia), working through 18 subsidiaries and a network of 110 distributor-partners. At year-end 2006, the company had more than 1,200 employees worldwide.*

**More information:** [www.vetoquinol.com](http://www.vetoquinol.com).

**OUR BUSINESS: ANIMALS. OUR ADVANTAGE: PEOPLE.**

For further information, contact

**VETOQUINOL**  
Finance Department  
Tel.: +33 (0)3 84 62 59 88  
[relations.investisseurs@vetoquinol.com](mailto:relations.investisseurs@vetoquinol.com)

**KEIMA COMMUNICATION**  
Investor Relations  
Emmanuel DOVERGNE  
Tel.: +33 (0)1 56 43 44 63  
[emmanuel.dovergne@keima.fr](mailto:emmanuel.dovergne@keima.fr)  
Media Relations  
Alix HÉRIARD DUBREUIL  
Tel.: +33 (0)1 56 43 44 62  
[alix.heriard@keima.fr](mailto:alix.heriard@keima.fr)